Biofrontera Valuation
| BFRI Stock | USD 0.82 0.02 2.50% |
Today, the firm appears to be overvalued. Biofrontera shows a prevailing Real Value of $0.71 per share. The current price of the firm is $0.82. Our model approximates the value of Biofrontera from analyzing the firm fundamentals such as Current Valuation of 11.06 M, profit margin of (0.47) %, and Return On Equity of -11.92 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Biofrontera's price fluctuation is abnormally volatile at this time. Calculation of the real value of Biofrontera is based on 3 months time horizon. Increasing Biofrontera's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Biofrontera is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Biofrontera Stock. However, Biofrontera's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.82 | Real 0.71 | Hype 0.82 | Naive 0.88 |
The intrinsic value of Biofrontera's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Biofrontera's stock price.
Estimating the potential upside or downside of Biofrontera helps investors to forecast how Biofrontera stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Biofrontera more accurately as focusing exclusively on Biofrontera's fundamentals will not take into account other important factors: Biofrontera Total Value Analysis
Biofrontera is currently projected to have valuation of 11.06 M with market capitalization of 9.59 M, debt of 4.92 M, and cash on hands of 31.91 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Biofrontera fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
11.06 M | 9.59 M | 4.92 M | 31.91 M |
Biofrontera Investor Information
About 12.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.65. Some equities with similar Price to Book (P/B) outperform the market in the long run. Biofrontera recorded a loss per share of 1.5. The entity had not issued any dividends in recent years. The firm had 1:20 split on the 5th of July 2023. Based on the key measurements obtained from Biofrontera's financial statements, Biofrontera is not in a good financial situation at this time. It has a very high odds of going through financial crisis in February.Biofrontera Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Biofrontera has an asset utilization ratio of 168.78 percent. This signifies that the Company is making $1.69 for each dollar of assets. An increasing asset utilization means that Biofrontera is more efficient with each dollar of assets it utilizes for everyday operations.Biofrontera Ownership Allocation
Biofrontera shows 12.18 percent of its outstanding shares held by insiders and 25.43 percent owned by other corporate entities.Biofrontera Profitability Analysis
The company reported the previous year's revenue of 37.3 M. Net Loss for the year was (17.76 M) with profit before overhead, payroll, taxes, and interest of 23.94 M.About Biofrontera Valuation
An absolute valuation paradigm, as applied to Biofrontera Stock, attempts to find the value of Biofrontera based on its fundamental and basic technical indicators. By analyzing Biofrontera's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Biofrontera's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Biofrontera. We calculate exposure to Biofrontera's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Biofrontera's related companies.Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts. Biofrontera operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 69 people.
Biofrontera Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 5.5 M | |
| Forward Price Earnings | 13.0039 |
Complementary Tools for Biofrontera Stock analysis
When running Biofrontera's price analysis, check to measure Biofrontera's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biofrontera is operating at the current time. Most of Biofrontera's value examination focuses on studying past and present price action to predict the probability of Biofrontera's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biofrontera's price. Additionally, you may evaluate how the addition of Biofrontera to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |